AI assistant
ImageneBio, Inc. — Director's Dealing 2021
Mar 26, 2021
34275_dirs_2021-03-25_0786edba-8177-4fb7-a04e-01ed79cd2c15.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Ikena Oncology, Inc. (IKNA)
CIK: 0001835579
Period of Report: 2021-03-25
Reporting Person: Dukes Iain D. (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.15 | 2026-08-23 | Common Stock (19061) | Direct | |
| Stock Option (Right to Buy) | $2.94 | 2028-02-14 | Common Stock (12707) | Direct | |
| Stock Option (Right to Buy) | $2.15 | 2028-12-17 | Common Stock (75639) | Direct | |
| Stock Option (Right to Buy) | $4.15 | 2029-03-19 | Common Stock (76595) | Direct | |
| Stock Option (Right to Buy) | $4.15 | 2029-10-17 | Common Stock (52418) | Direct |
Footnotes
F1: This option is fully vested and exercisable as of the date hereof.
F2: 25% of this option vested and became exercisable on January 8, 2019, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F3: 25% of this option vested and became exercisable on December 14, 2018, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F4: 25% of this option vested and became exercisable on March 20, 2020, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F5: 25% of this option vested and became exercisable on October 15, 2020, with the remainder vesting in 36 substantially equal monthly installments thereafter.